Boehringer Ingelheim and GoodRx are partnering for a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price exclusively on GoodRx.
The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as psoriasis, psoriatic arthritis, hidradenitis suppurativa, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Now, anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase Adalimumab-adbm at more than 70,000 retail pharmacies nationwide.
Beginning July 18, 2024, Boehringer and GoodRx are offering prices for both high-concentration and low-concentration citrate-free formulations of Adalimumab-adbm as a pre-filled syringe (10 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.8 mL or 40 mg/0.4 mL) or autoinjector (40 mg/0.8 mL or 40 mg/0.4 mL) at an exclusive cost of $550 per two-pack, which represents a 92% discount from the Humira list price.
